7RG0 Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Regulus Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.42 |
| 52 Week High | US$3.26 |
| 52 Week Low | US$1.02 |
| Beta | 1.63 |
| 11 Month Change | 10.08% |
| 3 Month Change | -10.13% |
| 1 Year Change | 20.34% |
| 33 Year Change | -55.06% |
| 5 Year Change | -81.07% |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7RG0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.4% | 0.8% | 0.8% |
| 1Y | 20.3% | -18.3% | 8.6% |
Return vs Industry: 7RG0 exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: 7RG0 exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 7RG0 volatility | |
|---|---|
| 7RG0 Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7RG0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7RG0's weekly volatility has decreased from 20% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 32 | Jay Hagan | www.regulusrx.com |
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Regulus Therapeutics Inc. Fundamentals Summary
| 7RG0 fundamental statistics | |
|---|---|
| Market cap | €95.03m |
| Earnings (TTM) | -€39.73m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.4x
P/E RatioIs 7RG0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7RG0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$22.62m |
| Gross Profit | -US$22.62m |
| Other Expenses | US$19.01m |
| Earnings | -US$41.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7RG0 perform over the long term?
See historical performance and comparison